Date: March 6, 2025
Source: The Hill
In a game-changing ruling, a federal judge in Texas has stopped compounding pharmacies from making affordable versions of Eli Lilly’s blockbuster weight loss drugs, Zepbound and Mounjaro. On March 5, 2025, Judge Mark Pittman upheld the FDA’s call that tirzepatide, the active ingredient in these GLP-1 drugs, is no longer in shortage. This ends a practice that let compounders offer lower-cost alternatives to these sought-after diabetes and obesity treatments.
For medspas, this is big news. Compounded drugs—cheaper than branded versions—were a go-to for many offering weight loss treatments. Now, smaller pharmacies must stop production immediately, and larger FDA-regulated outsourcing facilities have until March 19, 2025, to wind down. The decision came after the Outsourcing Facilities Association (OFA) sued the FDA, claiming the agency’s move jacked up drug prices and hurt patient access. Eli Lilly, meanwhile, cheered the ruling, slamming unapproved copies as risky.
What’s next? Medspa owners may face higher costs for branded drugs, potentially reshaping client care and pricing. A similar fight over semaglutide is still in play, so stay tuned. This shift could push medspas to rethink how they deliver these trending anti-obesity solutions.
The Florida “Shedspa” Story: Let’s Call This What It Really Is
A Florida woman was arrested for operating an unlicensed “medspa” in her backyard shed, causing facial paralysis in a patient. But calling this a medspa story misses the real issue: legitimate-looking practices that cut corners on sourcing while hiding in plain sight. The industry needs real oversight to protect compliant medspas from being lumped in with backyard operations.
John Oliver, Medspas, and the Uncomfortable Truths the Industry Can’t Ignore
John Oliver addresses the lack of oversight in the medspa indusry on Last Week tonight.
Suburban Boston in the Hot Seat: Milton Medspa Botulism Case Raises Serious Questions
10 case of botulism from Botox suspected from Canton, MA neighbor Milton. Read about the closer of Rodrigo Beauty plus more about the problem in this fast growing industry.
MY SALON Suite’s Growth in Minnesota Reveals a Shift in Medspa Business Models
As MY SALON Suite expands in Minnesota, it’s clear the medspa industry is shifting. From solo injectors in salon suites to mergers and partnerships, today’s medspa business models are more diverse than ever—and flexibility is the new standard.
FDA Cracks Down: Compounding Pharmacies Ordered to Stop Copying Ozempic and Wegovy
Medspas offering compounded semaglutide products must act fast after a major FDA ruling. Find out what this means for your business.
Beyond the Feds: Ohio Cracks Down on 14 Med Spas for Misleading Semaglutide Claims
Ohio Attorney General Dave Yost has warned 14 med spas for making misleading claims about compounded semaglutide drugs. Discover what your med spa needs to update to stay compliant.
